GLP-1 Ripple Effect: Reshaping Injectable Drug Delivery

Episode 46

0:00-33:22

The rapid evolution of biologics and blockbuster obesity therapies is creating an unprecedented demand on the injectable drug delivery market. As these treatments mature and reach millions of patients, the pharmaceutical industry is being forced to rethink dose volumes, supply chain sustainability, and device design. In this episode of Life Science Solutions, host Chris Adkins sits down with Paul Jansen, a recognized industry voice and veteran leader in medical device development and combination products. Drawing from his extensive background, including leadership roles at Sanofi, Paul explains how the massive success of GLP-1 therapies is shaking up the industry and forcing innovators to adapt. Topics Include: The GLP-1 Ripple Effect: Why the current model of one injection per device is environmentally and economically unsustainable for mass markets, driving the shift toward fixed-dose pens and the future of auto-indexing needles. The Rise of Dual Chamber Systems: How the expiration of key patents is opening the door for dual chamber cartridges, allowing for easier lyophilization reconstitution and the sequential delivery of complex, mixed therapies. Wearable Injectors: Why on-body wearables haven't hit their predicted "hockey stick" growth yet, and why the industry needs to focus on creating affordable, less-featured baseline devices rather than over-engineering them.

Publisher

Life Science Solutions

Link

share.transistor.fm/s/21350ecb

Published

June 23, 2026

Duration

33 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

Host

Kymanox

LS

Life Science Solutions

@lifesciencesolutions

#rippleeffect #reshapinginjectabledrug #lifesciences

The Nile